Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
198 hedge funds and large institutions have $3.17B invested in Momenta Pharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 79 increasing their positions, 53 reducing their positions, and 21 closing their positions.
1,765% more call options, than puts
Call options by funds: $20.6M | Put options by funds: $1.11M
138% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 21
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
49% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 53
36% more capital invested
Capital invested by funds: $2.33B → $3.17B (+$839M)
16% more funds holding
Funds holding: 170 → 198 (+28)
4.58% less ownership
Funds ownership: 103.79% → 99.21% (-4.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$60.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$59M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$53.9M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$30.2M |
| 5 |
BlackRock
New York
|
+$26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$78.1M |
| 2 |
Primecap Management
Pasadena,
California
|
-$65.7M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$53.1M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$50.4M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$34.8M |
MNTA Hedge Fund Activity: Q1 2020 in Review
198 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q1 2020, worth a combined $3.17B — up 36% from $2.33B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new MNTA positions and 21 closed out — a net gain of 29 holders — while 79 added to existing stakes and 53 trimmed.
The largest buyer was Maverick Capital, opening a new position worth an estimated $60.4M. The largest seller was Perceptive Advisors, cutting an estimated $78.1M.
- 198 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q1 2020, up from 170 in Q4 2019.
- Funds reported $3.17B of Momenta Pharmaceuticals, Inc. stock for Q1 2020, up 36% quarter-over-quarter.
- 50 funds opened new Momenta Pharmaceuticals, Inc. positions in Q1 2020 and 21 closed out, a net change of +29 holders.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q1 2020 was Maverick Capital, an estimated $60.4M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q1 2020 was Perceptive Advisors, an estimated $78.1M sold.
Based on aggregated 13F filings for Q1 2020.